Adc Therapeutics Stock News

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

Morgan Stanley increased its stake in ADC Therapeutics SA (NYSE:ADCT) by 22.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 249,527 shares of the companys stock after purchasing an additional 45,300 shares during the quarter. Morgan Stanley owned approximately 0.36% of ADC []

ADC Therapeutics SA (NYSE:ADCT) has been given a consensus recommendation of Buy by the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued []

Shares of ADC Therapeutics SA (NYSE:ADCT) dropped 6% during trading on Friday . The company traded as low as $26.21 and last traded at $26.21. Approximately 2,188 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 278,913 shares. The stock had previously closed at $27.88. ADCT has been []

ADC Therapeutics SA (ADCT) CEO Christopher Martin on Q3 2021 Results - Earnings Call Transcript

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 39.18% and 69.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BOSTON & SHANGHAI & LAUSANNE, Switzerland--(BUSINESS WIRE)--Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced the first

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted an

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted an

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematologic

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted an

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted an

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematologica

ADC Therapeutics SA (ADCT) CEO Christopher Martin on Q2 2021 Results - Earnings Call Transcript